SNDX-5613

SNDX-5613 (Revumenib) is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity.

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	900	In-stock
500mg	1300	In-stock
1g	1850	In-stock
3g	3950	In-stock
5g	5450	In-stock
10g	8275	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670


Synonyms	Revumenib
CAS No.	2169919-21-3
Purity	>98%
Formula	C32H47FN6O4S
Mol Weight	630.817
State	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
CoA	CoA of SNDX-5613


		Search